Evidence map›Paper›PMID 36612301›Full record

ArticleCancers2023

Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies.

Eliana-Ruobing Zhang, Sarah Ghezelbash, Pingxing Xie, Misha Fotovati, Ivan V Litvinov, Philippe Lefrançois

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eliana-Ruobing ZhangFaculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.ORCID 0000-0002-7358-1032
Sarah GhezelbashFaculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
Pingxing XieFaculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
Misha FotovatiFaculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
Ivan V LitvinovFaculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.ORCID 0000-0003-0562-4675
Philippe LefrançoisFaculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.ORCID 0000-0003-2939-7956
McGill University · CAJewish General Hospital · CA

Funding

Dr. Raymond and Dr. Leora Kahn Research Bursary in Memory of Mrs. Marion Kahn NAFonds de Recherche du Québec - Santé 312768Fonds de Recherche du Québec - Santé 324151Jewish General Hospital NAJewish General Hospital Foundation NALady Davis Institute for Medical Research NATerry Fox Research Institute 3253
6 · The paper itself

Abstract

Basal cell carcinoma (BCC) is the most common form of skin cancer, contributing to nearly a third of new cancer cases in Western countries. Most BCCs are considered low risk "routine" lesions that can either be excised through surgery or treated with chemotherapeutic agents. However, around 1-2% of BCC cases are locally aggressive, present a high risk of metastasis, and often develop chemoresistance, termed advanced BCC. There currently exists no animal model or cell line that can recapitulate advanced BCC, let alone intermediate-risk and high-risk early BCC. We previously found that aggressive BCC tumours presented a Th2 cytokine inflammation profile, mesenchymal stem cell properties, and macrophage-induced tumoral inflammation. In this study, we aimed to identify potential BCC "relatives" among solid-organ malignancies who present similar immune cell proportions in their microenvironment compositions. Using immune cell type deconvolution by CIBERSORTx, and cell type enrichment by xCell, we determined three cancers with the most similar tumour microenvironments as compared to BCC. Specifically, chromophobe renal cell carcinoma, sarcoma, and skin cutaneous melanoma presented significance in multiple cell types, namely in CD4+ T lymphocytes, gammadelta T lymphocytes, and NK cell populations. Consequently, further literature analysis was conducted to understand similarities between BCC and its "relatives", as well as investigating novel treatment targets. By identifying cancers most like BCC, we hope to propose prospective druggable pathways, as well as to gain insight on developing a reliable animal or cell line model to represent advanced BCC.

Indexed as

basal cell carcinomaBCCCIBERSORTcomputational biologygenomicsTCGAThe Cancer Genome Atlastumour microenvironmentxCell

Identifiers

PMID36612301
PMCPMC9818508
OpenAlexW4313472929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.